RxDoctor Payments Data

Matthew Hilton, DO

Family Medicine · Zeeland, MINPI 1699061564

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 69 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$388
  • Teva Pharmaceuticals USA, Inc.$189
  • AstraZeneca$181
  • Amgen$58
  • Astellas Pharma US Inc$44
  • Johnson & Johnson$43
  • plus $219 from 9 others

What the payments were for

  • Food & beverage$1,11099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$5,657
Medicare patients
40
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide33$45,444
EliquisApixaban34$27,715
FarxigaDapagliflozin Propanediol13$18,837
JardianceEmpagliflozin19$17,252
XareltoRivaroxaban19$14,417
Repatha SureclickEvolocumab14$11,464
Atorvastatin Calcium215$4,069
Tamsulosin Hcl104$2,942
Lisinopril150$2,043
Metoprolol Succinate61$1,469
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,327
Levothyroxine Sodium62$1,201
Losartan Potassium63$1,147
Ezetimibe30$1,089
Rosuvastatin Calcium50$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$17$45,44433 claims
PfizerEliquis$39$27,71534 claims
AstraZenecaFarxiga$181$18,83713 claims
Boehringer IngelheimJardiance$23$17,25219 claims
Johnson & JohnsonXarelto$43$14,41719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Zeeland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →